Medexus Pharmaceuticals (TSX:MDP) Net Income From Continuing Operations : C$4.9 Mil (TTM As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Medexus Pharmaceuticals's net income from continuing operations for the three months ended in Dec. 2024 was C$1.0 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was C$4.9 Mil.

Medexus Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Medexus Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Net Income From Continuing Operations Chart

Medexus Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Net Income From Continuing Operations

Get a 7-Day Free Trial

-6.56

-35.53

-3.65

1.67

-0.29

Medexus Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-0.72	1.03	2.68	0.15	1.04

Medexus Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$4.9 Mil.

Medexus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

MEDXF:USA P731:Germany

Address

10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3

Website

https://www.medexus.com

Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.

Executives

Brendon Buschman	Senior Officer
Mike Mueller	Director
Benoit Gravel	Director
Stephen William Nelson	Director
Kenneth D'entremont	Director, Senior Officer
Marcel Pascal Konrad	Senior Officer
Brian Peters	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Roland Boivin	Senior Officer
Michael Pine	Senior Officer
Glenn Tate	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Richard Labelle	Senior Officer
Benoît Hébert	Senior Officer